The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2–advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study.
 
Manish A. Shah
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Oncolys BioPharma (Inst)
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
 
Salah-Eddin Al-Batran
Stock and Other Ownership Interests - Institut für Klinische Krebsforschung GmbH
Consulting or Advisory Role - Bristol-Myers Squibb; Immutep; Lilly; MacroGenics; Merck Sharp & Dohme
Speakers' Bureau - AIO gGmbH; Bristol-Myers Squibb; Lilly; MCI Group
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Eurozyto; Federal Ministry of Education and Research; German Cancer Aid; German Research Foundation; Hospira; Immutep; Ipsen; Lilly; Medac; MSD Sharp & Dohme; Roche; Sanofi; Vifor Pharma
 
Yung-Jue Bang
Consulting or Advisory Role - Alexo Therapeutics; Astellas Pharma; AstraZeneca/MedImmune; BeiGene; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Green Cross; Hanmi; Merck Serono; MSD Oncology; Novartis; Samyang
Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Daiichi Sankyo (Inst); GC Pharma (Inst); Genentech/Roche (Inst); Genexine (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Daniel V.T. Catenacci
Honoraria - Amgen; Archer; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritstone Bio; Guardant Health; Lilly; Merck; Natera; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Seagen; Taiho Pharmaceutical; Tempus; Zymeworks
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Genentech/Roche; Guardant Health; Lilly; Merck; Seagen; Taiho Pharmaceutical; Zymeworks
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Genentech; Guardant Health; Lilly; Merck; Tempus
 
Peter C. Enzinger
Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb/Celgene; Celgene; Coherus Biosciences; Daiichi Sankyo; Five Prime Therapeutics; IDEAYA Biosciences; Istari; Legend Biotech; Lilly; loxo; Merck; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Turning Point Therapeutics; Xencor; Zymeworks
 
David H. Ilson
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; IQvia; Lilly/ImClone; Macrogenics; Merck; Pieris Pharmaceuticals; Roche/Genentech; Taiho Pharmaceutical
 
Sunnie S. Kim
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo/Lilly
Research Funding - Merck
 
Florian Lordick
Honoraria - Art Tempi; AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Incyte; Lilly; Medscape; Medupdate; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER; Streamedup!
Consulting or Advisory Role - Amgen; Astellas Pharma; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; SERVIER; Zymeworks
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly
 
Kohei Shitara
Honoraria - Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Janssen; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Eric Van Cutsem
Consulting or Advisory Role - Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst)
 
Ahsan Arozullah
Employment - Astellas Pharma
 
Jeffrey J. Raizer
Employment - Astellas Pharma
Stock and Other Ownership Interests - Agenus; Cancer Action Now; Exicure
 
Jung Wook Park
Employment - Astellas Pharma
 
Rui-hua Xu
No Relationships to Disclose